Vaginal Self-collection in Human Papillomavirus Testing
The data are now overwhelming that the most cost-efficient primary screen for women over the age of 30–35 should be a test for high-risk types of human papillomavirus. A self-collected sample expands coverage by overcoming many of the known obstacles to participation in a screening programme. In addition, self-sampling has the potential to be the most effective means to achieve high coverage rates in medically underserved regions of the world that lack the healthcare infrastructure to support traditional screening programmes. Self-collection combined with high throughput, low cost-per-case, polymerase chain reaction-based technology has the sensitivity of a direct endocervical sample obtained by a physician. Therefore, we have the technology to reach millions of women around the world in a short period of time through large ‘event-type’ screening programmes and centralised testing. Now we need to focus on developing the models that will enable us to efficiently place the technologies next to the women who need them the most.
Share this Article
Related Content In Gynaecological Cancers
Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?
touchREVIEWS in Oncology & Haematology. 2022;18(1):2–8 DOI: https://doi.org/10.17925/OHR.2022.18.1.2
Cervical cancer (CC) remains one of the most frequent cancers in women, representing the fourth cause of neoplasia in women in terms of incidence, and has a high lethality rate.1 Indeed, worldwide 341,831 women die each year because of this disease, with a mortality rate that varies across different countries, with, for example, less than two […]
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives
touchREVIEWS in Oncology. 2021;17(2):68–72 DOI: https://doi.org/10.17925/OHR.2021.17.2.68
Cervical cancer (CC) is the fourth most common female malignancy, with 640,127 new cases and 341,831 deaths in 2020 worldwide. Despite the introduction of screening programmes and vaccination campaigns, CC still represents one of the leading causes of cancer-related death in women.1 The appropriate treatment strategy is determined according to the stage of disease at […]
High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy
touchREVIEWS in Oncology & Haematology. 2021;17(1):23-27 DOI: https://doi.org/10.17925/OHR.2021.17.1.23
Endometrial cancer has become an increasingly significant cause of morbidity and mortality for women. Currently, endometrial cancer is the most common invasive gynaecologic malignancy, and the ninth most common cancer among women in the USA, accounting for approximately 65,620 new cancer cases and 12,590 deaths in 2020.1 The 5-year relative survival rate is estimated to be […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!